

CORRECTION

Open Access

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Clifford J Bailey^{1*}, Jorge L Gross², Delphine Hennicken³, Nayyar Iqbal⁴, Traci A Mansfield⁴ and James F List⁴

Correction

The authors [1] note that the standard errors in Table 3 (Table 1 here) are actually standard deviations. The reference to standard errors in the footnote has now been edited accordingly.

This is a Correction article on <http://www.biomedcentral.com/1741-7015/11/43>.

* Correspondence: c.j.bailey@aston.ac.uk

¹Life and Health Sciences, Aston University, Birmingham B4 7ET, UK
Full list of author information is available at the end of the article

Table 1 Summary of laboratory parameters

	PBO + MET (n = 137)	DAPA 2.5 mg + MET (n = 137)	DAPA 5 mg + MET (n = 137)	DAPA 10 mg + MET (n = 135)
Sodium (mmol/L)				
n	72	77	87	93
Baseline	138.9 (2.3)	138.5 (2.9)	138.6 (2.3)	139.1 (2.2)
Change at week 102	-0.04 (2.7)	0.2 (2.8)	0.1 (2.6)	0.1 (2.6)
<i>P</i> vs PBO + MET		0.1434	0.1905	0.3978
Potassium (mmol/L)				
n	72	77	87	93
Baseline	4.35 (0.47)	4.34 (0.46)	4.37 (0.39)	4.37 (0.43)
Change at week 102	-0.08 (0.55)	-0.01 (0.45)	-0.05 (0.35)	-0.07 (0.47)
<i>P</i> vs PBO + MET		0.3366	0.4563	0.9918
Serum creatinine (µmol/L)				
n	72	77	88	93
Baseline	76.9 (17.9)	78.7 (18.1)	79.6 (19.3)	77.8 (17.8)
Change at week 102	-0.9 (10.3)	-1.8 (9.7)	-3.5 (12.7)	-2.7 (10.6)
<i>P</i> vs PBO + MET		0.9954	0.4720	0.9032
Serum uric acid (µmol/L)^a				
n	28	35	47	57
Baseline	314 (79)	322 (80)	323 (88)	323 (80)
Change at week 102	-1.78 (54.13)	-55.9 (50.32)	-46.4 (64.36)	-52.9 (64.36)
<i>P</i> vs PBO + MET		0.0054	0.0013	0.0002
Blood urea nitrogen (mmol/L)				
n	72	77	88	93
Baseline	5.33 (1.55)	5.51 (1.41)	5.65 (1.81)	5.34 (1.41)
Change at week 102	0.56 (1.24)	0.70 (1.54)	0.42 (1.87)	0.73 (1.44)
<i>P</i> vs PBO + MET		0.2299	0.4169	0.0845
Haematocrit (%)				
n	71	78	87	93
Baseline	42.61 (3.90)	42.38 (3.99)	42.15 (3.59)	42.88 (3.95)
Change at week 102	-1.43 (3.29)	0.84 (2.53)	1.35 (2.48)	1.54 (2.78)
<i>P</i> vs PBO + MET		<0.0001	<0.0001	<0.0001
Haemoglobin (g/L)				
n	71	78	87	94
Baseline	142.8 (13.45)	142.5 (14.25)	141.6 (12.19)	143.6 (13.10)
Change at week 102	-4.9 (10.14)	1.5 (7.73)	3.1 (8.40)	4.1 (8.84)
<i>P</i> vs PBO + MET		<0.0001	<0.0001	<0.0001
Systolic blood pressure (mm Hg)				
n	72	78	88	94
Baseline	128 (15)	127 (14)	127 (14)	126 (16)
Change at week 102	1.5 (13.7)	0.7 (16.1)	-1.1 (13.2)	-0.3 (15.0)
<i>P</i> vs PBO + MET		0.1111	0.0136	0.0067

Table 1 Summary of laboratory parameters (Continued)

Diastolic blood pressure (mm Hg)				
n	72	78	88	94
Baseline	81 (9)	80 (9)	81 (9)	79 (10)
Change at Week 102	-1.0 (7.9)	-0.1 (8.1)	-1.5 (8.1)	-1.2 (10.1)
<i>P</i> vs PBO + MET		0.6605	0.2140	0.1075

Data are means (SD) at baseline or mean changes (SD) from baseline at week 102 including data after rescue unless noted. n is the number of treated patients with non-missing baseline and Week 102 values for the specific test. *Excluding data after rescue. Abbreviations: *SD* standard deviation, *SE* standard error, *PBO* placebo, *MET* metformin, *DAPA* dapagliflozin.

Author details

¹Life and Health Sciences, Aston University, Birmingham B4 7ET, UK.
²Endocrine Division, Universidade Federal do Rio Grande do Sul, Avenida Paulo Gama 110-Reitoria, Porto Alegre 90040-060, Brazil. ³Global Biometric Services, Bristol-Myers Squibb, Parc de l'Alliance, Avenue de Finlande 4, Braine l'Alleud B-1420, Belgium. ⁴Global Clinical Research, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ 08543, USA.

Received: 20 August 2013 Accepted: 20 August 2013
Published: 2 September 2013

Reference

1. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF: **Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.** *BMC Medicine* 2013, **11**:43.

doi:10.1186/1741-7015-11-193

Cite this article as: Bailey *et al.*: Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. *BMC Medicine* 2013 **11**:193.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

